Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

155 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus.
Kraaij T, Kamerling SWA, de Rooij ENM, van Daele PLA, Bredewold OW, Bakker JA, Bajema IM, Scherer HU, Toes REM, Huizinga TJW, Rabelink TJ, van Kooten C, Teng YKO. Kraaij T, et al. Among authors: van kooten c, van daele pla. J Autoimmun. 2018 Jul;91:45-54. doi: 10.1016/j.jaut.2018.03.003. Epub 2018 Apr 7. J Autoimmun. 2018. PMID: 29636274 Clinical Trial.
TBK1: A key regulator and potential treatment target for interferon positive Sjögren's syndrome, systemic lupus erythematosus and systemic sclerosis.
Bodewes ILA, Huijser E, van Helden-Meeuwsen CG, Tas L, Huizinga R, Dalm VASH, van Hagen PM, Groot N, Kamphuis S, van Daele PLA, Versnel MA. Bodewes ILA, et al. Among authors: van hagen pm, van helden meeuwsen cg, van daele pla. J Autoimmun. 2018 Jul;91:97-102. doi: 10.1016/j.jaut.2018.02.001. Epub 2018 Apr 16. J Autoimmun. 2018. PMID: 29673738
MxA is a clinically applicable biomarker for type I interferon activation in systemic lupus erythematosus and systemic sclerosis.
Huijser E, van Helden-Meeuwsen CG, Groot N, Bodewes ILA, Wahadat MJ, Schreurs MWJ, van Daele PLA, Dalm VASH, van Laar JAM, van Hagen PM, Waris M, Kamphuis S, Versnel MA. Huijser E, et al. Among authors: van hagen pm, van helden meeuwsen cg, van laar jam, van daele pla. Rheumatology (Oxford). 2019 Jul 1;58(7):1302-1303. doi: 10.1093/rheumatology/kez078. Rheumatology (Oxford). 2019. PMID: 30879072 No abstract available.
Long-term effects of combined B-cell immunomodulation with rituximab and belimumab in severe, refractory systemic lupus erythematosus: 2-year results.
Kraaij T, Arends EJ, van Dam LS, Kamerling SWA, van Daele PLA, Bredewold OW, Ray A, Bakker JA, Scherer HU, Huizinga TJW, Rabelink TJ, van Kooten C, Teng YKO. Kraaij T, et al. Among authors: van kooten c, van dam ls, van daele pla. Nephrol Dial Transplant. 2021 Jul 23;36(8):1474-1483. doi: 10.1093/ndt/gfaa117. Nephrol Dial Transplant. 2021. PMID: 32591783 Free PMC article.
Characteristics of COVID-19 infection and antibody formation in patients known at a tertiary immunology department.
Guchelaar NAD, van Laar JAM, Hermans MAW, van der Houwen TB, Atmaca S, van Maaren MS, Brkic Z, van Daele PLA, Dalm VASH, van Hagen PM, Rombach SM. Guchelaar NAD, et al. Among authors: van hagen pm, van laar jam, van der houwen tb, van maaren ms, van daele pla. J Transl Autoimmun. 2021;4:100084. doi: 10.1016/j.jtauto.2021.100084. Epub 2021 Jan 29. J Transl Autoimmun. 2021. PMID: 33532723 Free PMC article.
Autoantibodies in Sjögren's syndrome and its classification criteria.
Veenbergen S, Kozmar A, van Daele PLA, Schreurs MWJ. Veenbergen S, et al. Among authors: van daele pla. J Transl Autoimmun. 2021 Dec 27;5:100138. doi: 10.1016/j.jtauto.2021.100138. eCollection 2022. J Transl Autoimmun. 2021. PMID: 35024595 Free PMC article.
A randomized, phase II study of sequential belimumab and rituximab in primary Sjögren's syndrome.
Mariette X, Barone F, Baldini C, Bootsma H, Clark KL, De Vita S, Gardner DH, Henderson RB, Herdman M, Lerang K, Mistry P, Punwaney R, Seror R, Stone J, van Daele P, van Maurik A, Wisniacki N, Roth DA, Tak PP. Mariette X, et al. JCI Insight. 2022 Dec 8;7(23):e163030. doi: 10.1172/jci.insight.163030. JCI Insight. 2022. PMID: 36477362 Free PMC article. Clinical Trial.
Is imatinib mesylate a promising drug in systemic sclerosis?
van Daele PL, Dik WA, Thio HB, van Hal PT, van Laar JA, Hooijkaas H, van Hagen PM. van Daele PL, et al. Arthritis Rheum. 2008 Aug;58(8):2549-52. doi: 10.1002/art.23648. Arthritis Rheum. 2008. PMID: 18668570 Free article.
[Systemic mastocytosis: a heterogeneous disease].
Hermans MA, Verburg M, van Laar JA, van Hagen PM, Pasmans SG, van Daele PL. Hermans MA, et al. Ned Tijdschr Geneeskd. 2016;160:A9340. Ned Tijdschr Geneeskd. 2016. PMID: 27229688 Dutch.
Successful Tocilizumab Treatment for Scleritis.
Poelman HJ, Van Daele PLA, Rothova A. Poelman HJ, et al. Among authors: van daele pla. Ocul Immunol Inflamm. 2020;28(2):285-287. doi: 10.1080/09273948.2019.1617885. Epub 2019 Aug 14. Ocul Immunol Inflamm. 2020. PMID: 31411511
155 results